Evolocumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Evolocumab and local guidelines before prescribing.

PCSK9 inhibitor

Mechanism

PCSK9 inhibitor monoclonal antibody.

Uses

Familial hypercholesterolaemia, high-risk patients not at LDL target on maximal therapy.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Injection-site reactions, nasopharyngitis, influenza-like illness.

Interactions

Few.

Contraindications and cautions

Hypersensitivity

Monitoring

Lipids

Pregnancy and breastfeeding

Avoid unless essential

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Subcutaneous every 2 or 4 weeks; used per NICE criteria.

More from the textbook: uses, cautions and other points
Where it is discussed in the book